Dextenza has received a specific and permanent reimbursement J-code from the CMS, Ocular Therapeutix announced in a press release.
The code, J1096, will become effective Oct. 1.
Dextenza (dexamethasone ophthalmic insert 0.4 mg) is approved for the treatment of ocular inflammation and pain following ophthalmic surgery.
“We are pleased that CMS has issued a unique J-code for Dextenza and has done so one full quarter earlier than expected,” Antony Mattessich, Ocular Therapeutix president and CEO, said in the release. “Issuance of the J-code is important for the company as it now
Uncategorized